BONINE FASTER-ACTING- diphenhydramine hcl tablet 
WellSpring Pharmaceutical Corporation

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

BONINE®
MECLIZINE HYDROCHLORIDE • ANTIEMETIC

Active ingredient (in each tablet)

Diphenhydramine HCl 25 mg

Purpose

Antiemetic

Uses

for prevention and treatment of nausea, vomiting, Uses or dizziness associated with motion sickness

Warnings

Do not use

■ for children under 6 years of age unless

■ Do not use with any other product containing diphenhydramine, including one used on skin

Ask a doctor before use if you have

■ difficulty in urination due to enlargement of the prostate gland

■ glaucoma

■ difficulty in urination due to enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are

taking sedatives or tranquilizers.

When using this product

 marked drowsiness may occur

■ alcohol, sedatives, and tranquilizers may increase drowsiness

■ avoid alcoholic beverages

■ use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding

ask a health professional before use.

Keep out of reach of children

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

■ dosage should be taken 30 minutes before you begin motion activity.

■ adults and children 12 years and over: take 1 to 2 tablets with Water every 4 to 6 hours, not to exceed 12 tablets (300 milligrams) in 24 hours, or as directed by a doctor.

■ Children 6 to under 12 years of age: take 1 tablet with Water every 4 to 6 hours, not to exceed 6 tablets (150 milligrams) in 24 hours, or as directed by a doctor.

Other information

■ Each tablet contains: Calcium 60mg 

■ Store at 25°C (77°F); excursions permitted between 15° - 30°C (59° - 86°F)

■ protect from moisture

■ see end flap for expiration date and lot number

Inactive ingredients

Croscarmellose sodium, dibasic calcium phosphate dihydrate, FD&C blue #1, aluminum lake, magnesium stearate, microcrystalline cellulose, silicone dioxide, stearic acid

Questions?

1-844-241-5454 or www.bonine.com

TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN. Keep Carton for important drug facts information.

Distributed by: WellSpring
Pharmaceutical Corporation
Sarasota, FL 34243
©2023 WellSpring
Pharmaceutical Corporation

Money Back Guarantee

PRINCIPAL DISPLAY PANEL 65197-616-16

NEW

9X the Adventure**

Diphenhydramine HCl - Antiemetic 25 mg

Prevents & Treats:

Vomiting  •  Nausea  •  Dizziness • Motion Sickness

*See back panel reference

* Than Meclizine HCL 25 mg per onset of action from The U.S. National Library of Medicine (NLM)

** Results may vary

FASTER-ACTING* RELIEF

TAKE WITH WATER

Bonine Faster Acting IFC

Bonine Faster Acting 2.0

BONINE  FASTER-ACTING
diphenhydramine hcl tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:65197-616
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40) (DIPHENHYDRAMINE - UNII:8GTS82S83M) DIPHENHYDRAMINE HYDROCHLORIDE25 mg
Inactive Ingredients
Ingredient NameStrength
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)  
DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)  
FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
STEARIC ACID (UNII: 4ELV7Z65AP)  
Product Characteristics
ColorblueScoreno score
ShapeROUNDSize9mm
FlavorImprint Code WS1
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:65197-616-162 in 1 BOX05/01/2023
18 in 1 BLISTER PACK; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph finalpart33605/01/2023
Labeler - WellSpring Pharmaceutical Corporation (110999054)

Revised: 7/2022
Document Id: ac542c3b-c73b-4782-9fca-a5fc05836f1a
Set id: 2c6f014d-6d46-4f8a-9196-904639dcb899
Version: 5
Effective Time: 20220706
 
WellSpring Pharmaceutical Corporation